亚洲健康人群CYP2C19等位基因发生率的合并分析_《中国循证医学杂志》

作者：

张爱玲 ^1,2 , 杨莉萍 ¹ ,  胡欣 ¹

1. 沈阳药科大学药学院（沈阳 110016）；2. 卫生部北京医院药学部（北京 100730;

关键词：

CYP2C19 等位基因发生率亚洲

DOI：

10.7507/1672-2531.2013024

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　对亚洲人群CYP2C19等位基因发生率的相关文献进行合并分析，为个体化药物治疗和药物基因组学研究提供依据。
方法　计算机检索PubMed、EMbase、Cochrane图书馆、CNKI、WanFang Data、VIP和CBM等数据库，纳入CYP2C19等位基因发生率的相关文献。按照纳入与排除标准筛选文献、提取数据后进行合并分析。
结果　共纳入41篇文献，包含17个国家9841例健康亚洲人的CYP2C19等位基因的信息。按东亚（中国、韩国和日本）、东南亚（越南、泰国、马来西亚、新加坡、缅甸、印度尼西亚和菲律宾）、南亚（印度）和西亚（巴勒斯坦、黎巴嫩、沙特阿拉伯、土耳其、伊朗和约旦）分区域进行分析，主要研究结果如下：CYP2C191、2和3等位基因的发生率，中国人群（n=4170）分别为61.3%、32.1%和6.6%；东亚人群（n=5879）分别为61.0%、31.2%和7.8%；东南亚人群（n=1985）分别为67.6%、28.8%和3.7%；南亚人群（n=679）分别为64.0%、35.2%和0.8%；西亚人群（n=1298）分别为87.3%、12.1% 和0.6%；亚洲以上四个地区17个国家9841例CYP2C191、2和3等位基因的总发生率分别为66.0%、28.4%和5.5%。
结论　CYP2C19各等位基因的发生率在我国及亚洲不同区域之间均存在较大差异（P lt;0.05），且遗传变异也会受地域环境的影响。

引用本文： 张爱玲,杨莉萍,胡欣. 亚洲健康人群CYP2C19等位基因发生率的合并分析. 中国循证医学杂志, 2013, 13(12): 1431-1439. doi: 10.7507/1672-2531.2013024 复制

1. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.

2. Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.

3. PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.

4. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.

5. Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.

6. 杨莉萍, 谢婧, 刘瑶, 等. CYP2C19*2、*3基因多态性与氯吡格雷临床疗效相关性的系统评价. 中国循证医学杂志, 2012, (09): 1063-1070.

7. Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.

8. Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.

9. Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.

10. Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.

11. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

12. Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.

13. Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.

14. 郭志强. 基于 CYP 多态性的氯吡格雷-质子泵抑制剂相互作用研究. 西安: 第四军医大学, 2010.

15. 胡玉荣. 兰索拉唑在国人不同基因型个体内的药动学. 郑州: 郑州大学, 2003.

16. 邵华, 刘乃丰, 周东蕊, 等. 双色荧光杂交芯片技术检测CYP2C19单核苷酸多态性. 中国新药与临床杂志, 2009, 28(4): 249-253.

17. 闫春兰, 詹金彪, 陈枢青. 浙江省汉族与畲族CYP2C19基因多态性研究. 中国药学杂志, 2004, (11): 70-72.

18. 周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测. 中国临床药理学与治疗学, 2007, (02): 208-213.

19. Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.

20. Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.

21. 李永芳, 杨梅, 寇毅英. 青海撒拉族人群CYP2C19基因多态性研究. 中国药学杂志, 2012, 47(07): 539-42.

22. He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.

23. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

24. 陈华芳. 细胞色素CYP2C19 (P4502C19) 基因多态性与食管癌易感性的关系. 福州: 福建医科大学, 2006.

25. 张林. CYP2C19基因多态性分析及其与奥美拉唑疗效关系的临床研究. 吉林: 吉林大学, 2004.

26. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.

27. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.

28. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.

29. Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.

30. Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.

31. Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.

32. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.

33. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.

34. Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.

35. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.

36. Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.

37. Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.

38. Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.

39. Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.

40. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.

41. Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.

42. Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.

43. Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.

44. Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.

45. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.

46. Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.

47. Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.

48. Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.

49. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.

50. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

1. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.

2. Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.

3. PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.

4. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.

5. Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.

6. 杨莉萍, 谢婧, 刘瑶, 等. CYP2C19*2、*3基因多态性与氯吡格雷临床疗效相关性的系统评价. 中国循证医学杂志, 2012, (09): 1063-1070.

7. Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.

8. Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.

9. Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.

10. Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.

11. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

12. Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.

13. Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.

14. 郭志强. 基于 CYP 多态性的氯吡格雷-质子泵抑制剂相互作用研究. 西安: 第四军医大学, 2010.

15. 胡玉荣. 兰索拉唑在国人不同基因型个体内的药动学. 郑州: 郑州大学, 2003.

16. 邵华, 刘乃丰, 周东蕊, 等. 双色荧光杂交芯片技术检测CYP2C19单核苷酸多态性. 中国新药与临床杂志, 2009, 28(4): 249-253.

17. 闫春兰, 詹金彪, 陈枢青. 浙江省汉族与畲族CYP2C19基因多态性研究. 中国药学杂志, 2004, (11): 70-72.

18. 周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测. 中国临床药理学与治疗学, 2007, (02): 208-213.

19. Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.

20. Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.

21. 李永芳, 杨梅, 寇毅英. 青海撒拉族人群CYP2C19基因多态性研究. 中国药学杂志, 2012, 47(07): 539-42.

22. He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.

23. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

24. 陈华芳. 细胞色素CYP2C19 (P4502C19) 基因多态性与食管癌易感性的关系. 福州: 福建医科大学, 2006.

25. 张林. CYP2C19基因多态性分析及其与奥美拉唑疗效关系的临床研究. 吉林: 吉林大学, 2004.

26. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.

27. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.

28. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.

29. Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.

30. Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.

31. Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.

32. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.

33. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.

34. Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.

35. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.

36. Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.

37. Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.

38. Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.

39. Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.

40. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.

41. Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.

42. Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.

43. Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.

44. Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.

45. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.

46. Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.

47. Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.

48. Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.

49. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.

50. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

上一篇
硒与大骨节病相关性的Meta分析

下一篇
CYP3A5基因型与肾移植患者他克莫司血药浓度关系的系统评价

1资料与方法

1.1一般资料

1.2方法

1.3察指标和判定标准

1.4统计学方法

2结果

2.1两组患者疗效比较

2.2两组患者换药次数、导管留置时间、治愈时间比较

2.3两组患者治疗前后血清PCT、CRP、WBC水平比较

3讨论

《中国循证医学杂志》

亚洲健康人群CYP2C19等位基因发生率的合并分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

1.	Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.
2.	Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.
3.	PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.
4.	Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.
5.	Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C192 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.
6.	杨莉萍, 谢婧, 刘瑶, 等. CYP2C192、3基因多态性与氯吡格雷临床疗效相关性的系统评价. 中国循证医学杂志, 2012, (09): 1063-1070.
7.	Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.
8.	Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.
9.	Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.
10.	Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.
11.	Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.
12.	Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.
13.	Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.
14.	郭志强. 基于 CYP 多态性的氯吡格雷-质子泵抑制剂相互作用研究. 西安: 第四军医大学, 2010.
15.	胡玉荣. 兰索拉唑在国人不同基因型个体内的药动学. 郑州: 郑州大学, 2003.
16.	邵华, 刘乃丰, 周东蕊, 等. 双色荧光杂交芯片技术检测CYP2C19单核苷酸多态性. 中国新药与临床杂志, 2009, 28(4): 249-253.
17.	闫春兰, 詹金彪, 陈枢青. 浙江省汉族与畲族CYP2C19基因多态性研究. 中国药学杂志, 2004, (11): 70-72.
18.	周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测. 中国临床药理学与治疗学, 2007, (02): 208-213.
19.	Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.
20.	Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.
21.	李永芳, 杨梅, 寇毅英. 青海撒拉族人群CYP2C19基因多态性研究. 中国药学杂志, 2012, 47(07): 539-42.
22.	He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.
23.	Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.
24.	陈华芳. 细胞色素CYP2C19 (P4502C19) 基因多态性与食管癌易感性的关系. 福州: 福建医科大学, 2006.
25.	张林. CYP2C19基因多态性分析及其与奥美拉唑疗效关系的临床研究. 吉林: 吉林大学, 2004.
26.	Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.
27.	Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.
28.	Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.
29.	Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.
30.	Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.
31.	Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.
32.	Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.
33.	Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.
34.	Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.
35.	Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.
36.	Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.
37.	Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.
38.	Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.
39.	Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.
40.	Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.
41.	Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.
42.	Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.
43.	Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.
44.	Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.
45.	Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.
46.	Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.
47.	Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.
48.	Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C191 and CYP2C192 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.
49.	Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.
50.	Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

《中国循证医学杂志》

亚洲健康人群CYP2C19等位基因发生率的合并分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料